341 related articles for article (PubMed ID: 22952427)
1. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
2. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
3. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
[TBL] [Abstract][Full Text] [Related]
4. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
5. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
6. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
7. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
8. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
9. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract][Full Text] [Related]
10. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
12. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
13. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Pathologic, and Genetic Features of Wilms Tumors With WTX Gene Mutation.
Alexandrescu S; Akhavanfard S; Harris MH; Vargas SO
Pediatr Dev Pathol; 2017; 20(2):105-111. PubMed ID: 28326956
[TBL] [Abstract][Full Text] [Related]
15. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
16. WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1.
Duhme C; Busch M; Heine E; de Torres C; Mora J; Royer-Pokora B
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e180-e183. PubMed ID: 31876779
[TBL] [Abstract][Full Text] [Related]
17. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
18. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
19. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
Brown KW; Charles A; Dallosso A; White G; Charlet J; Standen GR; Malik K
Cancer Genet; 2012 Jun; 205(6):319-26. PubMed ID: 22749038
[TBL] [Abstract][Full Text] [Related]
20. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
